StockData
PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30

Propanc Biopharma, Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.32−0.03 (-7.31%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

Propanc Biopharma, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Propanc Biopharma does not break out revenue by segment, region or product in the tagged data of its filings for this period type.